Integra LifeSciences Holdings Corporation — Fiscal 2010 Form 10-K
Reporting period: Fiscal year ended December 31, 2010. The filing was signed February 23, 2011. Although the request references 2010 Q4, this is an annual Form 10-K; fourth-quarter information is included where relevant.
Business context
Integra is a global medical-device company serving orthopedic, neurosurgical, spine, reconstructive, wound-care and general-surgery markets. It reports one operating segment and sells through direct sales forces, distributors, wholesalers and strategic partners. Regenerative-medicine products represented approximately 23% of 2010 revenue. The company employed approximately 3,000 people at year-end.
Financial performance and position
| Metric | 2010 | 2009 | Change |
|---|---|---|---|
| Revenue | $732.1 million | $682.5 million | +7% |
| Gross profit | $463.9 million | $437.6 million | +6% |
| Gross margin | 63.4% | 64.1% | Down 70 bps |
| Operating income | $98.7 million | $97.8 million | +1% |
| Net income | $65.7 million | $51.0 million | +29% |
| Diluted EPS | $2.17 | $1.74 | +25% |
| Operating cash flow | $105.6 million | $143.2 million | Down $37.7 million |
| Capital expenditures | $37.1 million | $25.2 million | Higher investment |
- Revenue by category: Orthopedics $290.1 million, up 11%; Neurosurgery $275.0 million, up 7%; and Instruments $167.0 million, up 2%.
- Geography: U.S. revenue was $561.2 million, or 77% of total revenue. International revenue was $170.8 million, or 23%, up 5% year over year.
- Fourth quarter: Revenue was $194.1 million versus $183.5 million in fourth-quarter 2009; net income was $18.8 million versus $15.7 million. Fourth-quarter revenue was seasonally stronger because of hospital budget-cycle purchasing.
- Balance sheet: Cash and equivalents were $128.8 million; total assets were $1.017 billion; stockholders’ equity was $500.0 million; goodwill was $261.9 million; and net intangible assets were $194.9 million.
- Debt and liquidity: Senior credit-facility borrowings totaled $248.1 million, consisting of $100.0 million revolving borrowings and $148.1 million term debt. The company also had $155.2 million of carrying-value convertible securities, principally the $165.0 million 2.375% senior convertible notes due 2012. Approximately $350.0 million remained available under the credit facility.
- Net debt position: Cash less senior credit-facility borrowings and convertible securities was negative $274.5 million at year-end.
Material changes versus the prior comparable period
- Revenue growth accelerated to 7% from 4% in 2009, led by extremity reconstruction, regenerative medicine, orthopedic implants and improved hospital capital spending in neurosurgery.
- Gross margin declined from 64.1% to 63.4% because of higher production and engineering costs associated with manufacturing-improvement projects, partly offset by a favorable product mix.
- Operating income increased only modestly because higher selling, general and administrative expenses, research and development spending and systems costs offset gross-profit growth.
- Net income benefited from lower interest expense following repayment of the 2010 convertible notes in June 2010, a $4.5 million tax benefit from settlement of uncertain tax positions and tax-law changes, and higher revenue.
- Operating cash flow decreased substantially because of working-capital investment, including higher receivables, inventory and prepaid expenses.
- In August 2010, Integra amended and restated its senior credit facility, increasing total capacity, adding a $150.0 million term loan, extending maturity to August 2015 and revising covenants.
- Integra repurchased approximately 858,000 shares for $31.3 million during 2010. A new authorization allowed up to $75.0 million of additional repurchases through December 31, 2012.
- 2010 acquisitions included the surgical-headlight assets of Welch Allyn and Australian distribution assets from Culley for approximately $2.4 million and $1.6 million, respectively.
Guidance, outlook and management commentary
- Management expected 2011 gross margin to improve through manufacturing efficiencies, better yields, lower costs and continued growth in higher-margin orthopedic implant and biomaterial products.
- Expected gross-margin gains were to be reinvested in regenerative-medicine production capacity during 2011 and 2012.
- Planned 2011 capital expenditures were $40 million to $50 million, primarily for regenerative-medicine capacity, enterprise-resource-planning upgrades and orthopedic instrument kits.
- Management anticipated approximately $100 million of 2011 repayments under the revolving credit facility and expected existing cash, operating cash flow and available borrowing capacity to meet foreseeable requirements for at least twelve months.
- Research and development spending, excluding special charges, was targeted at approximately 6.5% to 7% of revenue, focused on spine, neurosurgery and extremity reconstruction.
- Management expected 2011 effective tax rate of approximately 20% to 21% and selling, general and administrative expenses, excluding special charges, of approximately 40% to 42% of revenue.
Risks, contingencies and unusual items
- Medical-device operations are subject to extensive FDA, international regulatory, quality-system, tissue-product and reimbursement requirements. Proposed changes to the FDA 510(k) process could increase testing, clinical-data and approval requirements.
- Demand is exposed to hospital budgets, elective-procedure volumes, third-party reimbursement, healthcare cost-containment measures and potential U.S. medical-device excise taxes scheduled for 2013.
- Competition is intense across spine, orthopedics, neurosurgery and instruments, including competition from physician-owned spinal distributorships and larger device companies.
- Products using bovine collagen and human tissue face additional sourcing, disease-transmission, tissue-banking and country-specific regulatory risks.
- Acquisition-related goodwill and intangible assets were significant. The company reported $261.9 million of goodwill and $49.7 million of indefinite-lived intangible assets and warned that impairment charges could be material if revenue, cash-flow or valuation assumptions deteriorate.
- Total 2010 special charges were $21.1 million, including $7.1 million of non-cash convertible-debt interest amortization, $3.5 million of systems and restructuring-related costs, $2.5 million of acquisition-related charges, $2.2 million related to the new chief operating officer and $0.9 million of intangible-asset impairment.
- Integra accrued $3.4 million related to a dispute over a Theken acquisition earn-out. The seller’s representative alleged $5.7 million was owed as of January 2011; management believed no additional amount was due for the second performance year.
- Product-liability claims had $2.1 million of accruals, offset by insurance receivables. Management stated that ordinary-course claims were not expected to be material, but acknowledged that contingencies could affect results in a particular period.
- Interest-rate, foreign-exchange, supply-chain, manufacturing interruption, product-liability, intellectual-property and cybersecurity or enterprise-system risks could affect future results. An interest-rate swap covered a $148.1 million notional amount of variable-rate debt.
Most important facts for investors to verify
- Whether margin expansion and manufacturing efficiencies materialize while capacity spending increases.
- The repayment schedule and covenant headroom for the $248.1 million senior credit-facility balance and the $165.0 million convertible notes due 2012.
- Operating-cash-flow conversion, inventory and receivables growth, and the effect of planned capital expenditures.
- Progress and returns from regenerative-medicine capacity expansion and recently acquired businesses.
- Exposure to reimbursement reductions, FDA 510(k) reform, the scheduled medical-device excise tax and physician-owned spinal distributorships.
- Resolution of the Theken earn-out dispute and any developments in product-liability, regulatory or intellectual-property matters.
- Potential future impairment charges affecting the company’s substantial goodwill and intangible-asset balances.